Institut Bergonié

Quick facts

Marketed products

• target treatment · Oncology
  This drug targets the CDK4/6 pathway to inhibit cancer cell proliferation.

Phase 3 pipeline

• At the discretion of the investigator
  The mechanism of this drug is not specified.
• Ifosfamide or dacarbazine · Oncology
  Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation.

Phase 2 pipeline

• undefined · Other

Phase 1 pipeline

• Combination of trabectedin with durvalumab
• Phase 1: Trabectedin
• Phase 2 : Avelumab

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Institut Bergonié portfolio CI brief
• Institut Bergonié pipeline updates RSS